Chromosome 2p22 over hmsh2 gene amplification and high expression of Taxol resistance in ovarian cancer research.docVIP

 PAGE \* MERGEFORMAT 15 Chromosome 2p22 over hmsh2 gene amplification and high expression of Taxol resistance in ovarian cancer research Authors: Li Hongxia, Guan S, Su-Mei Zhang, Yin Dong Mei 【Abstract】 Objective To study the DNA copy of chromosome region-specific changes in differential gene expression and taxol resistance relationship. Methods of comparative genomic hybridization (comparative genomic hybridization, CGH), and RT  PCR technology, analysis of ovarian cancer, paclitaxel drug-resistant strains genomic changes and hmsh2 genes in ovarian cancer tissues. The results of CGH results showed that the most significant change is the Taxol-resistant ovarian cancer cell lines OC3/Tax300 over-amplification of chromosome 2p22. RT  PCR detected hmsh2 gene is highly expressed in OC3/Tax300 cells. hmsh2 gene expression positive rate in Group 1 and group 2 were 93.9% (31/33) and 47.6% (10/21), the difference was significant; in poorly differentiated carcinoma was 93.3%, significantly higher than that in well-differentiated carcinoma of 54.2%. Conclusion 2p22 copy number of over-amplification and hmsh2 gene highly expressed in ovarian cancer may be related to Taxol resistance-associated. Keywords: Ovarian cancer; taxol-resistant cell line; comparative genomic hybridization; hmsh2 gene Fund Project: Capital Medical Development Scientific Research Fund (key subjects) funded project (ZD199915) Study on the Relationship of Taxol  resistance of Ovarian Carcinoma with the Amplification of 2p22 on Chromosome and the Expression of hmsh2 Gene. Keywords:: Ovarian carcinoma; Taxol  resistant cell lines; CGH; hmsh2 gene Ovarian cancer is the highest mortality of gynecological malignancies. At present, its treatment, its exact effect of paclitaxel has become the most widely used chemotherapy drugs, one, and cis-platinum, no cross-resistance between doxorubicin, has become the treatment of ovarian cancer in first-line drugs. Ho